Gennova's Omicron-specific booster vaccine gets DCGI approval

The Department of Biotechnology (DBT) has facilitated establishing the vaccine manufacturing for developingthe platform technology from proof of concept till Phase I clinical trial of the prototype mRNA-based vaccine developed against the Wuhan strain.

Union Minister Jitendra Singh commended the efforts and said, "I take great pride in DBT fulfilling its mission yet again – enabling technology-driven entrepreneurship through creating this indigenous mRNA-platform technology. We have always supported technology-driven innovation towards the creation of a 'future-ready' technology platform in line with the Prime Minister’s vision of Aatmanirbharta."

He also said, "Infrastructure to deploy vaccine in India, including LMICs, at 2‑8°C exist today & this innovation is tailored for the existing established supply-chain Infrastructure. The vaccine does not need ultra-low temperature conditions for transport and storage."

Gennova Biopharmaceuticals CEO  Dr. Sanjay Singh, said India has now developed two mRNA vaccines against COVID-19.

"I am proud that my team has worked tirelessly over the last two years to develop the nation's first mRNA vaccine. This is a team effort & without the guidance of the Subject Expert Committee of CDSCO and the Vaccine Expert Committee of BIRAC monitoring the project, it would not have been possible."